Drug Type Fusion protein |
Synonyms- |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Burkitt Lymphoma | Phase 1 | - | - | |
Burkitt Lymphoma | Phase 1 | - | - | |
Diffuse Large B-Cell Lymphoma | Phase 1 | - | - | |
Diffuse Large B-Cell Lymphoma | Phase 1 | - | - | |
Mantle-Cell Lymphoma | Phase 1 | - | - | |
Mantle-Cell Lymphoma | Phase 1 | - | - |
Phase 1 | 3 | Yttrium Y 90-DOTA-Biotin+Etoposide+Carmustine+Melphalan+Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein+Clearing Agent+Cytarabine | wdpriencfi(suacmchnui) = amxpsrafhn oqiwnsbvmk (mysylcwcif, ulkumzzevg - cfmbobsbgr) View more | - | 23 Nov 2020 |